TY - JOUR
T1 - Atherosclerosis Treatment with Stimuli-Responsive Nanoagents
T2 - Recent Advances and Future Perspectives
AU - Maruf, Ali
AU - Wang, Yi
AU - Yin, Tieyin
AU - Huang, Junli
AU - Wang, Nan
AU - Durkan, Colm
AU - Tan, Youhua
AU - Wu, Wei
AU - Wang, Guixue
PY - 2019/6/6
Y1 - 2019/6/6
N2 - Atherosclerosis is the root of approximately one-third of global mortalities. Nanotechnology exhibits splendid prospects to combat atherosclerosis at the molecular level by engineering smart nanoagents with versatile functionalizations. Significant advances in nanoengineering enable nanoagents to autonomously navigate in the bloodstream, escape from biological barriers, and assemble with their nanocohort at the targeted lesion. The assembly of nanoagents with endogenous and exogenous stimuli breaks down their shells, facilitates intracellular delivery, releases their cargo to kill the corrupt cells, and gives imaging reports. All these improvements pave the way toward personalized medicine for atherosclerosis. This review systematically summarizes the recent advances in stimuli-responsive nanoagents for atherosclerosis management and its progress in clinical trials.
AB - Atherosclerosis is the root of approximately one-third of global mortalities. Nanotechnology exhibits splendid prospects to combat atherosclerosis at the molecular level by engineering smart nanoagents with versatile functionalizations. Significant advances in nanoengineering enable nanoagents to autonomously navigate in the bloodstream, escape from biological barriers, and assemble with their nanocohort at the targeted lesion. The assembly of nanoagents with endogenous and exogenous stimuli breaks down their shells, facilitates intracellular delivery, releases their cargo to kill the corrupt cells, and gives imaging reports. All these improvements pave the way toward personalized medicine for atherosclerosis. This review systematically summarizes the recent advances in stimuli-responsive nanoagents for atherosclerosis management and its progress in clinical trials.
KW - atherosclerosis
KW - nanoagents
KW - stimuli-responsiveness
UR - http://www.scopus.com/inward/record.url?scp=85063802106&partnerID=8YFLogxK
U2 - 10.1002/adhm.201900036
DO - 10.1002/adhm.201900036
M3 - Review article
C2 - 30945462
AN - SCOPUS:85063802106
SN - 2192-2640
VL - 8
JO - Advanced healthcare materials
JF - Advanced healthcare materials
IS - 11
M1 - 1900036
ER -